MARKET

CORT

CORT

Corcept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.18
+0.05
+0.38%
Opening 13:53 01/24 EST
OPEN
13.13
PREV CLOSE
13.13
HIGH
13.35
LOW
13.12
VOLUME
415.58K
TURNOVER
--
52 WEEK HIGH
17.48
52 WEEK LOW
9.14
MARKET CAP
1.51B
P/E (TTM)
18.69
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CORT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CORT News

  • Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
  • Zacks.01/09 13:40
  • Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
  • Zacks.01/08 15:18
  • Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
  • Zacks.01/07 15:21
  • Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
  • Zacks.01/07 14:51

More

Industry

Pharmaceuticals
-1.61%
Pharmaceuticals & Medical Research
-1.78%

Hot Stocks

Name
Price
%Change

About CORT

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
More

Webull offers Corcept Therapeutics Incorporated (CORT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.